Drug
YESCARTA
YESCARTA is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_2
2
67%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
completed267%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_2
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
NCT03642626
completedphase_2
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
NCT04071366
completed
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
NCT05349201
Clinical Trials (3)
Showing 3 of 3 trials
NCT03642626Phase 2
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
NCT04071366Phase 2
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
NCT05349201
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3